247 related articles for article (PubMed ID: 19414394)
1. Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.
Okarvi SM; Jammaz IA
Anticancer Res; 2009 Apr; 29(4):1399-409. PubMed ID: 19414394
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
3. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
4. Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: A potential candidate for the targeting of breast carcinoma.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2016 Jul; 43(7):403-9. PubMed ID: 27179249
[TBL] [Abstract][Full Text] [Related]
5. Preparation and
Okarvi SM; Aljammaz I
Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent.
Okarvi SM
J Pept Res; 2004 Jun; 63(6):460-8. PubMed ID: 15175018
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
Okarvi SM; Jammaz IA
Nucl Med Biol; 2012 Aug; 39(6):795-804. PubMed ID: 22381782
[TBL] [Abstract][Full Text] [Related]
8. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
9. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
Facca VJ; Al-Saden N; Ku A; Reilly RM
Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and comparative assessment of a labeled RGD peptide bearing two different ⁹⁹mTc-tricarbonyl chelators for potential use as targeted radiopharmaceutical.
Psimadas D; Fani M; Gourni E; Loudos G; Xanthopoulos S; Zikos C; Bouziotis P; Varvarigou AD
Bioorg Med Chem; 2012 Apr; 20(8):2549-57. PubMed ID: 22445386
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.
Liu S; Hsieh WY; Jiang Y; Kim YS; Sreerama SG; Chen X; Jia B; Wang F
Bioconjug Chem; 2007; 18(2):438-46. PubMed ID: 17341108
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, and biological evaluation of (99m) Tc(CO)3 -labeled peptides for potential use as tumor targeted radiopharmaceuticals.
Baishya R; Nayak DK; Chatterjee N; Halder KK; Karmakar S; Debnath MC
Chem Biol Drug Des; 2014 Jan; 83(1):58-70. PubMed ID: 23679852
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent.
Okarvi SM; al-Jammaz I
Anticancer Res; 2003; 23(3B):2745-50. PubMed ID: 12894569
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, Radiolabeling, and Preclinical Evaluation of
Okarvi SM; Al-Jammaz I
Cancer Biother Radiopharm; 2022 Jun; 37(5):372-383. PubMed ID: 35325547
[No Abstract] [Full Text] [Related]
15. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
16. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
[TBL] [Abstract][Full Text] [Related]
17. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma.
Retzloff LB; Heinzke L; Figureoa SD; Sublett SV; Ma L; Sieckman GL; Rold TL; Santos I; Hoffman TJ; Smith CJ
Anticancer Res; 2010 Jan; 30(1):19-30. PubMed ID: 20150613
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of
Maleki F; Masteri Farahani A; Sadeghzadeh N; Mardanshahi A; Abediankenari S
Chem Biol Drug Des; 2020 Nov; 96(5):1223-1231. PubMed ID: 32426902
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
